Tai, Y. T. & Anderson, K. C. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget 8, 112166–112167 (2017). Article PubMed PubMed Central Google Scholar DeFrancesco, L. CAR-T cell therapy seeks strategies to harness cytokine storm. Nat. Biotechnol. 32, 604 (2014). Article...
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T-cell activity against large B-cell lymphoma The CD38/CD28xCD3 trispecific antibody SAR442257 boosted CART-cell activity through recognition of CD38 on the tumor, costimulation of CART-cells, and induced fratricide of CD38 T-cells....
Several approaches focusing on T-cell mediated myeloma cell killing, such as CAR-T-cells2 and bispecific T-cell engagers3 are currently being investigated as therapy for these patients. In addition, the introduction of anti-CD38 mAbs (ie, daratumumab and isatuximab) has significantly influenced ...
2、anti-CD3ε 激动剂抗体可以引起 T 细胞激活并释放细胞因子,但是这类抗体也有一些限制因素。第一,高亲和力的抗体会激活高水平的细胞因子释放,导致细胞因子风暴,这也是 CAR-T 和 T 细胞连接子的负反应;第二,CD3 激活是 T 细胞分化的两个信号之一,但是只激活这一个信号会导致激活的细胞死亡,限制了长久的抗肿...
Article Open access 11 January 2022 IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control Article 05 February 2025 Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Article Open access 23 February 2021 Data...